Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Radiation Boost Linked to Better Survival in Rectal Cancer

A phase 2 trial finds that adding a modest radiation boost improves 9-year survival without increasing toxicity, despite no improvement in pathologic complete response.

Creatinine Assay Bias Affects MELD Scoring

Bilirubin interference in commonly used creatinine assays artificially inflates MELD scores in liver transplant candidates, a study reports.

EHR Marker May Help Curb Risk for Liver Transplant Rejection

A remote intervention aimed at improving medication adherence may reduce organ rejection in liver transplant recipients at high risk.

Altimmune Drug Cuts Heavy Drinking in Mid-stage Trial for Alcohol Use Disorder

Altimmune said on Tuesday its experimental drug helped patients with alcohol use disorder cut back on heavy drinking ⁠in a mid-stage trial, sending the company's shares 10%...

Newer Antibiotics Show No Clear Benefit for Staph Infections

A new meta-analysis finds ceftaroline and ceftobiprole monotherapy show no clear advantage over standard therapy for non-urinary Staphylococcus aureus infections.

FDA Approves Freenome's Blood Test for Colorectal Cancer Screening

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way ⁠for partner Abbott to launch it in the U.S. this fall,...

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Latest News

A phase 2 trial finds that adding a modest radiation boost improves 9-year survival without increasing toxicity, despite no improvement in pathologic complete response.

Bilirubin interference in commonly used creatinine assays artificially inflates MELD scores in liver transplant candidates, a study reports.

A remote intervention aimed at improving medication adherence may reduce organ rejection in liver transplant recipients at high risk.

Altimmune said on Tuesday its experimental drug helped patients with alcohol use disorder cut back on heavy drinking ⁠in a mid-stage trial, sending the company's shares 10%...

A new meta-analysis finds ceftaroline and ceftobiprole monotherapy show no clear advantage over standard therapy for non-urinary Staphylococcus aureus infections.

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way ⁠for partner Abbott to launch it in the U.S. this fall,...

News All Time

Low-Volume PEG Wins for Inpatient Bowel Cleansing

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Why the Painless Abdominal Bloating in Middle-Age Man?

Admitted for pyelonephritis, but his diagnostic journey is just beginning

Beware Aspiration Risk in Chronic Pot Users

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Unusual Confluence of Two Rare Syndromes Results in Peculiar Symptoms

Interpretation of an ultrasound exam made all the difference in creating a treatment plan

Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

— Results highlight importance of careful evaluation of concurrent medications, researchers say

Q&A: Managing GI Toxicities of Immunotherapy

Gastrointestinal side effects are among the most important issues to address with patients starting on immune checkpoint inhibitors.

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Steatosis and Cardiovascular Events; Golimumab Biosimilar OK'd; Daily Stress and IBS

News and commentary from the world of gastroenterology and hepatology

GLP-1s Linked to Lower Risk of Cancer Spread in Four Tumor Types

Accumulating evidence of possible benefit warrants randomized trials, experts say

Danish Duo's Maverick African Research Finds Its Moment in RFK Jr.'s Vaccine Policy

"They became more strident in saying that their findings were real," says one expert

FDA OKs First Treatment for Chronic Hepatitis D Infection

In phase III study, patients taking bulevirtide had ALT normalization and steep drops in HDV RNA

Perfusion Preservation Strategy Boosts Liver Transplant Outcomes

Portal-venous hypothermic oxygenated perfusion reduced incidence of early allograft dysfunction

Blood Test for Colon Cancer Screening Gets Guideline Backing

Updated ACS guidance suggests use in those who decline other options

GLP-1s and Chronic Pancreatitis; Hypoglycemia After Bowel Prep; Lower GI Bleeding

News and commentary from the world of gastroenterology and hepatology

Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials

Findings "will change the landscape" of treatment, researcher says

Recommended News For You

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

On all CAR-T products, the FDA is calling for a new boxed warning.

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

New First-Line Option for Advanced ALK-Positive Lung Cancer

In inflammatory breast cancer, ER beta regulates estrogen signaling.

Since 2000, the outlook for multiple myeloma has improved.

Recommended Articles For You

Community Cancer Awareness Through Survivor Advocacy Networks 

Unlocking the Potential of Cancer Antigen 19-9 for Early Detection 

Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology 

Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients

2.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

3.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record

4.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

5.

New Standard of Care in High-Risk Acute Promyelocytic Leukemia?

1.

Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome

2.

Survivorship Care Planning Beyond Active Cancer Treatment: Advancing Care Continuity for Cancer Survivors

3.

Unlocking the Potential of Etoposide: A Novel Approach to Cancer Treatment

4.

New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results

5.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

2.

Navigating the Complexities of Ph Negative ALL - Part XII

3.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

4.

Navigating the Complexities of Ph Negative ALL - Part IX

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot